Nemysis Limited Announces Successful IHAT-Gut Trial
In this Phase II trial, Nemysis' novel oral iron supplement IHAT (Iron Hydroxide Adipate Tartrate) was compared to both ferrous sulphate (FeSO4), the current gold standard iron supplement, and a placebo.
- In this Phase II trial, Nemysis' novel oral iron supplement IHAT (Iron Hydroxide Adipate Tartrate) was compared to both ferrous sulphate (FeSO4), the current gold standard iron supplement, and a placebo.
- Dr. Cristina Comelli, R&D Director at Nemysis, remarks: "We are delighted about the publication of the trial results.
- Danilo Casadei-Massari, Nemysis' Chairman and CEO, states: "We are excited by the continued success of IHAT as a leading therapy for people suffering from iron deficiency.
- With the success of this clinical trial, we are one step closer to providing an improved route to recovery from iron deficiency and its associated anaemia."